Key Points
- CEO Roger Susi sold 5,000 shares on March 16 at an average price of $101.38 for a total of $506,900, trimming his stake by 0.22% to 2,242,500 shares valued at about $227.3M (SEC filing).
- iRadimed beat Q4 estimates with EPS of $0.54 (vs. $0.49) and revenue of $22.69M, issued Q1 2026 guidance of 0.440–0.480 EPS and FY2026 guidance of 2.060–2.210 EPS, and raised its quarterly dividend to $0.20 from $0.17.
- The stock slid about 3%, trading near $99.67 with a market cap of $1.27B and a P/E of 56.95, and carries a consensus “Moderate Buy” rating with a $120 price target from analysts.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $102.43, for a total transaction of $256,075.00. Following the completion of the transaction, the chief executive officer owned 2,240,000 shares of the company's stock, valued at approximately $229,443,200. This trade represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
iRadimed Stock Performance
Shares of NASDAQ:IRMD opened at $99.67 on Thursday. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $107.90. The firm has a market cap of $1.27 billion, a PE ratio of 56.95 and a beta of 1.12. The firm's fifty day moving average is $100.46 and its 200-day moving average is $89.23.
iRadimed (NASDAQ:IRMD - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The business had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.
iRadimed Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were issued a $0.20 dividend. The ex-dividend date was Monday, February 23rd. This is a boost from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed's dividend payout ratio (DPR) is currently 45.71%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its position in shares of iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 397 shares during the period. CWM LLC increased its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 211 shares in the last quarter. Quarry LP bought a new stake in iRadimed during the 3rd quarter valued at $40,000. State of Alaska Department of Revenue acquired a new position in iRadimed during the third quarter worth $47,000. Finally, Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares during the last quarter. Institutional investors own 92.34% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on IRMD. Lake Street Capital restated a "buy" rating and issued a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings restated a "buy (b-)" rating on shares of iRadimed in a report on Monday, December 29th. Finally, Roth Mkm reaffirmed a "buy" rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $120.00.
Get Our Latest Report on iRadimed
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
